Sana Biotechnology Inc. (NASDAQ:SANA) is a must-buy penny stock according to analysts. On November 7, Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating on Sana Biotechnology (NASDAQ: SANA) and set a price target of $6.00. Sana Biotechnology (SANA) Wins Analyst Support With Strategic Focus and Cash Strength Pressmaster/Shutterstock.com TD Cowen analyst Marc Frahm also maintained a Buy rating on Sana Biotechnology Inc., citing the company’s decision to focus on its high‑potential S ...

Eve Holding Inc. (NYSE:EVEX) is a must-buy penny stock to buy now. On November 5, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating on Eve Holding Inc. (NYSE:EVEX), impressed by the company’s progress in the electric Vertical Takeoff and Landing (eVTOL) market. Additionally, Cannacord Genuity analyst Austin Moeller reiterated a Buy rating on the stock on November 6 and set a $7.50 price target. This is Why Eve Holding Inc. (EVEX) is a Buy Despite Wider Than Expected Q3 Net Loss While the company ...

Nuvation Bio Inc. (NYSE:NUVB) is a must-buy penny stock to buy now. On November 4, H.C. Wainwright analyst Robert Burns reiterated a Buy rating on the stock and set a $10 price target. The Buy rating was issued after Nuvation Bio Inc. (NYSE:NUVB) announced the enrollment of 204 new patients in its trial of IBTROZI, a cancer therapy for non‑small cell lung cancer. Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress Copyright: dolgachov / 123RF Stock Photo The enrollme ...

Alight Inc. (NYSE:ALIT) is a must-buy penny stock to buy now. On November 6, analysts on Wall Street reiterated a “Buy” rating on the stock, despite Alight Inc. (NYSE:ALIT) delivering disappointing third-quarter financial results. UBS analyst Kevin McVeigh maintained a Buy rating on the stock, with a $4 price target. Peter Heckmann of D.A. Davidson echoed a Buy rating, also with a $6 price target. Wall Street Bullish on Alight Inc. (ALIT) amid Disappointing Q3 Results Photo by John on Unsplash The posit ...

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren Amin reaffirmed his Buy rating on Taysha Gene Therapies, assigning a $9 price target. On November 5, Truist Financial analyst Joon Lee also reaffirmed a Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) following the company’s third‑quarter results. Taysha Gene Therapies Inc. (TSHA) Net Loss Widens But Touts FDA Milestone and Financial Strength Photo by CDC on Unsplash On Novem ...

Good morning. We’re a day late to our weekly lookahead, which we’ve been trying to do more routinely. Good news: There’s still lots of week left! Bad news: There’s still lots of week left! Today, we’ll cover off all the files that will help make Friday come a little faster.Up firstIn the newsDeals: Ottawa is pushing Anglo American PLC to redomicile to Canada as it reviews the British miner’s proposed acquisition of Teck Resources Ltd., two sources familiar with the matter told The Globe and Mail. Defence: A ...

Compass Therapeutics Inc. (NASDAQ:CMPX) is a must-buy penny stock to buy now. On November 10, Pipe Sandler analyst Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is a Buy and set a $12 price target. The positive stance stems from the company’s announcement that it has made significant progress in developing its clinical pipeline. Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development adriaticfoto/Shutterstock.com HC Wainwright analyst Joseph Pantginis ...

Atai Beckley NV (NASDAQ:ATAI) is a must-buy penny stock to buy now. On November 12, TD Cowen’s Ritu Baral reaffirmed a Buy rating on Atai Beckley NV (NASDAQ:ATAI), pointing to encouraging clinical progress and solid financial footing. Positive Phase 2b results for BPL‑003 in treatment‑resistant depression, a favorable safety profile, and the choice of an 8mg dose for Phase 3 trials strengthen confidence in the program. With a cash runway extending to 2029, recent equity financing, expected FDA feedback, an ...

Rezolve AI PLC (NASDAQ:RZLV) is one of the top stocks offering high upside potential in data centers and AI. On November 7, Northland Securities analyst Michael Latimore reaffirmed his Buy rating on Rezolve AI PLC (NASDAQ:RZLV), assigning a $7 price target. Rezolve AI PLC (RZLV) Secures $200M to Enhance AI Commerce in Europe and the US Source: unsplash Earlier on November 5, Rezolve AI PLC announced the expansion of its commercial operations across the US and Europe, securing $200 million in financing. ...

Benitec Biopharma Inc. (NASDAQ:BNTC) is one of the best breakout stocks to invest in. On November 4, an analyst at Citizens JMP raised the stock’s price target to $22 from $20 while reiterating an Outperform rating. The price target hike follows topline clinical data results that showed a 100% response rate for BB-301 in Phase 1b/2a of the treatment for Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle-wasting disease. Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Res ...